| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
|---|
| CuraAX |
| nOH in Parkinson’s & related conditionsα1A-AR agonist NCE | |
| CuraCN |
| Neurodegenerative DiseaseCombo β2-AR agonist | |
| CuraXN |
| Neurodegenerative DiseaseCombo β2-AR agonist NCE | |
| CuraAX |
|---|
| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
| nOH in Parkinson’s & related conditionsα1A-AR agonist NCE |
|
| CuraCN |
|---|
| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
| Neurodegenerative DiseaseCombo β2-AR agonist |
|
| CuraXN |
|---|
| IND-enabling | Phase 1 | Phase 2a | Phase 2b | Phase 3 |
| Neurodegenerative DiseaseCombo β2-AR agonist NCE |
|
nOH (neurogenic Orthostatic Hypotension)
